Abstract
Increasing resistance to antifungal therapy is an impediment to the effective treatment of fungal infections. Candida glabrata is an opportunistic human fungal pathogen that is inherently less susceptible to cost-effective azole antifungals. Gain-of-function mutations in the Zn finger pleiotropic drug resistance transcriptional activator-encoding gene CgPDR1 are the most prevalent causes of azole resistance in clinical settings. CgPDR1 is also transcriptionally activated upon azole exposure; however, factors governing CgPDR1 gene expression are not yet fully understood.
Funding Information
  • Department of Biotechnology, Ministry of Science and Technology, India (BT/HRD/NBA/37/01/2014)
  • Wellcome Trust DBT India Alliance (IA/S/15/1/501831)
  • DST | Science and Engineering Research Board (EMR/2016/005375)

This publication has 71 references indexed in Scilit: